nach oben

Erschienen in:

Open Access 01.10.2016 | Molecular Imaging (J Wu and P Nguyen, Section Editors)

Molecular Imaging of Angiogenesis in Cardiac Regeneration

verfasst von: Ljubica Mandic, Denise Traxler, Alfred Gugerell, Katrin Zlabinger, Dominika Lukovic, Noemi Pavo, Georg Goliasch, Andreas Spannbauer, Johannes Winkler, Mariann Gyöngyösi

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 10/2016

Abstract

Purpose of Review

Myocardial infarction (MI) leading to heart failure displays an important cause of death worldwide. Adequate restoration of blood flow to prevent this transition is a crucial factor to improve long-term morbidity and mortality. Novel regenerative therapies have been thoroughly investigated within the past decades.

Recent Findings

Increased angiogenesis in infarcted myocardium has shown beneficial effects on the prognosis of MI; therefore, the proangiogenic capacity of currently tested treatments is of specific interest. Molecular imaging to visualize formation of new blood vessels in vivo displays a promising option to monitor proangiogenic effects of regenerative substances.

Summary

Based on encouraging results in preclinical models, molecular angiogenesis imaging has recently been applied in a small set of patients. This article reviews recent literature on noninvasive in vivo molecular imaging of angiogenesis after MI as an integral part of cardiac regeneration.

This article is part of the Topical Collection on Molecular Imaging

Introduction

Heart failure following myocardial infarction (MI) still displays a major cause of death and disability worldwide [1]. Even though a wide range of therapeutic options to prevent or delay transition to chronic heart failure (CHF) after MI are available, its treatment is still unsatisfactory, as CHF is generally not reversible and treatment needs to be continued indefinitely [2]. Angiogenesis, the formation of new blood vessels, is a part of the natural healing process after MI to restore blood flow and discard cellular debris [3]. The extent of angiogenesis is associated with postinfarct remodeling and has implications on prognosis in MI patients [4]. Although a variety of approaches to stimulate myocardial angiogenesis after MI have been explored, including gene therapy as well as the delivery of angiogenic factors and stem cells, results have been controversial and were partly disappointing [5‐7]. In many cases, stimulation of angiogenesis was not shown convincingly and only moderate clinical improvement was demonstrated. To reliably assess the therapeutic potential of proangiogenic therapies and monitor myocardial angiogenesis for enabling better preclinical and clinical drug development, noninvasive methods such as molecular imaging are warranted. Molecular imaging of newly built microvessels is a promising strategy which allows direct visualization of vessel formation instead of indirect measurements of efficacy. Thus, it is an important modality for improving risk stratification and for facilitating the development of novel therapeutic interventions in MI patients.

Angiogenesis

Angiogenesis represents the growth of new capillaries from preexisting vessels [8]. It is a complex process involving numerous growth factors and signal cascades [9]. Although vessels are generally quiescent in adults, endothelial cells (ECs) lining the vessel walls retain their ability to respond to angiogenic signals [8]. Proangiogenic signals such as VEGF, ANG-2, FGFs, or chemokines released by hypoxic, inflammatory, or tumor cells activate ECs, and they become motile and invasive [10]. Before ECs can sprout into surrounding tissue, degradation of basement membrane by matrix metalloproteases and detachment of mural cells is necessary in order to loosen activated ECs [8]. VEGF induces increased permeability of the EC layer, and extravasated plasma proteins serve as a provisional extracellular matrix (ECM) scaffold. Migration of ECs into this scaffold is mediated by integrins. To allow blood flow, those newly built vessels need to be connected with other vessels to build branches and become mature and stable. ECs regain their quiescent state and protease inhibitors cease basement membrane degradation [10].

Insufficient vessel maintenance can lead to MI [10]. Intact and functional blood vessels are essential for regeneration of ischemic tissues to enable immune surveillance, supply of oxygen and nutrients to and discarding of waste from the cells of the healing wound [10, 11]. Insufficiently healed MI results in an expanded infarction area and dilation of the heart by left ventricular (LV) remodeling, both resulting in heart failure [12]. However, in some patients, recovery of blood flow after MI is not possible. In those patients, restoration of tissue reperfusion depends on myocardial angiogenesis [1]. Within the first hours after MI, proangiogenic factors are released to compensate ischemia with induced angiogenesis [11]. Restoration of the blood flow in the infarct border zone is essential to alleviate infarct expansion and heart failure [1, 13]. Moreover, the extent of angiogenesis has positive effects on postinfarct remodeling and the prognosis of MI patients [4]. Hence, stimulation of myocardial angiogenesis as a therapeutic option through administering growth factors, stem or progenitor cells, and pharmacological molecules has been thoroughly studied [14]. Due to the increasing amount of research on myocardial angiogenesis as a treatment option, molecular imaging of newly built vessels has a significant potential impact on predicting outcome of MI patients and guiding novel therapies.

Molecular Imaging Tools

Molecular imaging describes in vivo targeted, noninvasive visualization and quantification of various molecular pathways without interfering with them [15‐18]. Throughout the past decades, there has been significant advances in molecular imaging techniques used for diagnostic, prognostic, as well as therapeutic purposes [18]. In the field of cardiology, molecular imaging by magnetic resonance imaging (MRI), ultrasound, bioluminescence imaging, positron emission tomography (PET), and SPECT has shown improvements of LV function, myocardial perfusion, viability, scar tissue, inflammatory cells, and indirect signs of angiogenesis, and some of these images are able to directly detect angiogenesis [15].

Nuclear Imaging

PET imaging is a tomographic technique that detects the decay of positron emitters (radiotracers), which can be attached to small molecules for molecular recognition [17, 19]. It is well validated to have superior sensitivity, relatively high resolution, and tissue penetration [19 20•]. Various metabolic and pathophysiological biomarkers have been investigated as targets for PET imaging. The nonspecific metabolic tracer ¹⁸F (in form of 18-fluorodeoxyglucose), ¹⁸F-FDG, is the most frequently employed PET tracer [21, 22]. Many studies are directed toward incorporation of radiotracers with short half-lives, such as fluorine-18 (¹⁸F), which successfully leads to reduced patient exposure of ionizing radiation [23]. Rather low spatial resolution is the main limiting characteristic of this imaging technique [21].

SPECT imaging is well established and offers several advantages over PET. Camera equipment is less expensive and more widely available as compared to PET systems [23]. SPECT imaging performance is based on using single photon emitting radioisotopes, which are easier accessible for the investigation of a wider range of biological processes [15, 24]. Technetium-99m (^99mTc) and indium-111 (¹¹¹In) are frequently used radioactive probes [19]. These radiotracers emit gamma rays with different energies, thus introducing the possibility of simultaneous evaluation of dual or multiple radiotracers. Advantages of SPECT are high sensitivity and tissue penetration depth. However, SPECT imaging does not ensure high-resolution anatomical information of cellular location. Another disadvantage is the inability to track radioisotopes over weeks as the signal rapidly declines [19].

MRI

In contrast to PET and SPECT, MRI offers better spatial resolution, excellent soft tissue contrast and enables concomitant angiography or perfusion acquisition [21]. However, it has a lower sensitivity for detection of molecular contrast agents and application is limited in patients with devices, e.g., cardiac pacemakers or cardioverter defibrillators, and metal implants [15, 25]. Paramagnetic contrast agents (e.g., gadolinium) targeting integrin α_vβ₃ via antibodies or peptidomimetics as well as gadolinium-based lipid nanoparticles, have been previously used to study tumor angiogenesis [26‐28]. A further advance in MR angiogenesis imaging are ultra-small superparamagnetic particles of iron oxide (USPIO) [29]. However, USPIOs have a long blood half-life and show nonspecific extravasation [30]. Microparticles of iron oxide (MPIO) have a higher particle size, and thus a shorter half-life, offering a better contrast to noise ratio [31]. Safety concerns of superparamagnetic iron oxide particles exist [32].

Ultrasound Molecular Imaging

Cardiac ultrasound is a widely used technique that has several advantages over the previously described imaging modalities, e.g., lack of ionizing radiation, routine accessibility, and superior spatial resolution compared to SPECT and PET [33]. Hitherto tissue perfusion assessed by ultrasound has been used as an endpoint reflecting angiogenesis; however, an increase in perfusion does not necessarily reflect angiogenic activity [34]. For more detailed imaging, targeted microbubbles can be used as contrast agents in a technique known as contrast-enhanced ultrasound (CEU) [33]. Microbubbles that target integrins or VEGFRs reflect angiogenesis in a more direct manner than perfusion imaging [34, 35].

Bioluminescence Imaging

Bioluminescence imaging (BLI) represents an indirect cell labeling method particularly used in small animal models [36]. It is greatly valued for its high sensitivity, ease of use, and low cost of instrumentation, but BLI has low spatial resolution and restricted penetration depth, and quantification accuracy is very poor [37, 38]. Most frequently used reporter genes are firefly luciferase (Luc) and herpes simplex virus thymidine kinase (HSV-tk), used for tracking cells with angiogenic capacity [39].

Multimodal Imaging

Advances in molecular imaging, along with identifying drawbacks, have led to the development of multimodal (hybrid) imaging systems such as PET/MR, SPECT/computed tomography (CT), and PET/CT [18]. Hybrid molecular imaging is the focus of many preclinical and clinical studies as it enables simultaneous collection of anatomical and functional information [40, 41].

The addition of CT to SPECT has permitted attenuation correction and better evaluation of SPECT myocardial perfusion [42]. SPECT/CT has proven to be relevant in the characterization of coronary artery calcium, which is a useful method to predict cardiovascular events rate [43, 44]. Even though SPECT/CT has been widely used in cardiology and information gained with this modality are highly valued, exposure of patients to radiation is a major concern [45] and reduction of radiation is the main goal of present studies in nuclear cardiology [46].

PET/CT is a hybrid technology that combines functional molecular imaging modalities with precise anatomical information [47]. This hybrid modality is successful in overcoming low spatial resolution. Many studies indicate that it results in better identification of diseases, and guide management and treatment of patients with stable and unstable coronary artery disease compared to PET imaging alone [48].

Molecular Imaging of Myocardial Angiogenesis

Within the past decade, direct noninvasive evaluation of angiogenesis by molecular imaging has been investigated extensively. With the rapid development of antiangiogenic therapies (e.g., in cancer research) and particularly imaging techniques, tumor angiogenesis has been the focus of attention lately [49]. Although interest has recently increasingly been directed on molecular imaging of myocardial angiogenesis after MI (e.g., to monitor effects of regenerative therapies), it is still rather in its fledgling stage. Table 1 provides a summary of novel studies on molecular imaging of angiogenesis.

Table 1

A summary of novel studies in molecular imaging of angiogenesis

	Radiotracer	Modality	Target	Therapy	Species	Disease
Myocardial
Preclinial	⁶⁸Ga-NODAGA-RGD ⁶⁸Ga-TRAP(RGD)₃ ¹⁸F-galacto-RGD [50]	PET	α_vβ₃ integrin	None	Rat	MI
	⁶⁸Ga-NOTA-RGD peptidomimetic [51]	PET	α_vβ₃ integrin	None	Rat	MI
	¹⁸F-Alfatide II [20•]	PET	α_vβ₃ integrin	VEGF, BMSC	Rat	MI
	⁶⁸Ga-RGD [52•]	PET	α_vβ₃ integrin	Dissociated HUVECs/cbMSCs or 3D HUVEC/cbMSC aggregates	Rat	MI
	¹¹In-DTPA-cNGR [53]	SPECT	CD13	None	Mouse	MI
	⁶⁴Cu-NOTA-TRC105 [54]	PET	CD105	None	Rat	MI
	[¹¹C]ATV-1[9]	PET	VEGFR-2, Tie-2, PDGFα	None	Rat	MI
Clinical	⁶⁸Ga-PRGD2 [55••]	PET	α_vβ₃ integrin	None	Human	MI
Hind limb
Preclinical	α_v targeted microbubbles [34]	Ultrasound	α_v integrins	HIF-1α mutants	Mouse	Ischemic hind limb
Tumor
	c(RGDyK)-MPIO [56•]	MRI	α_vβ₃ integrin	None	Mouse	Melanoma, colon carcinoma
	⁶⁸Ga-aquibeprin [57••]	PET	α₅β₁ integrin	None	Mouse	melanoma

Angiogenesis as a multistep process, orchestrated by a wide range of growth factors, growth factor receptors, cell types, adhesion molecules, integrins, and signaling pathways, all of which offer a multitude of imaging targets. In general, three ways to image myocardial angiogenesis exist: (1) non-EC targets, (2) EC targets, and (3) extracellular matrix proteins and matrix proteases [58]. In particular, integrin α_vβ₃ has emerged as an interesting target.

Integrins

Integrins are structurally and functionally diverse families of cell adhesion molecules, which regulate cell-cell and cell-ECM interactions and in addition mediate signals for cell growth, proliferation, migration, or apoptosis [59]. They connect the ECM with the cytoskeleton (i.e., the microfilaments) inside the cell and transmit signals of the surrounding into the cell by mediating the downstream consequences of cell adhesion. Therefore, integrins play an important role in cell signaling and can have a relation to cell growth, cell division, cell survival, differentiation, and apoptosis [60]. Several members of the integrin family are overexpressed on ECs under hypoxia [61]. The two main integrins α_vβ₃ and α₅β₁ facilitate several mechanisms during angiogenesis in tissue ischemia. In particular, they mediate adhesion to ECM and other cells to initiate building of new capillaries by allowing ECs to bind to provisional ECM scaffold proteins. Furthermore, they mediate interaction of ECs and vascular smooth muscle cells, stimulate vessel growth, and promote vessel maturation [10, 61]. ECM proteins such as fibronectin interact with integrins via the Arg-Gly-Asp (RGD) sequence motif [61]. Multivalent binding is mediated through extracellular integrin clusters, and thus, dimeric and multimeric RGD sequences with improved binding affinity have been developed and are frequently used for integrin imaging.

Integrin α_vβ₃

Integrin α_vβ₃-mediated imaging is currently the most frequently applied method to visualize angiogenesis in vivo. Its expression is low in normal tissue, but it becomes highly expressed in activated ECs during angiogenesis in the infarcted myocardium [61, 62]. However, studies in α_v- and β₃-deficient mice suggest that both integrins are not essentially required for angiogenesis and their absence can be compensated by upregulation of VEGFR-2 expression [63‐65]. Additionally, integrin α_vβ₃ does not seem to be restricted to ECs but is also expressed on macrophages so that results in angiogenesis imaging targeting integrin α_vβ₃ need to be treated with caution [66].

For integrin α_vβ₃ molecular imaging, cyclic RGD dimers with polyethylene glycol spacers radiolabeled with ¹⁸F [67, 68], ⁶⁸Ga [69, 70], ⁶⁴Cu [71], ⁷⁶Br [72], and ⁸⁹Zr [73] for PET imaging and ^99mTc [74, 75] and ¹¹¹In [76] for SPECT imaging were used in several disease entities. Within the past years, the use of these and other tracer probes that had been investigated predominantly in tumor angiogenesis has been translated to angiogenesis imaging after MI for evaluating proangiogenic effects of regenerative therapies. In a previous study, ¹⁸F-galacto-RGD injected in a rat MI model predicted improved healing [77]. The usage of this tracer, however, might be limited as the production of ¹⁸F-galacto-RGD is complex and time-consuming. ⁶⁸Ga tracers, on the other hand, are easy to handle and fast in production. ⁶⁸Ga-NODAGA-RGD and ⁶⁸Ga-TRAP-(RGD)₃ have been previously tested for angiogenesis imaging in tumor models [78, 79]. Both ⁶⁸Ga-RGD tracers were compared to ¹⁸F-galacto-RGD in postinfarct myocardial angiogenesis, and uptake was similar in all three groups (Fig. 1), indicating that ⁶⁸Ga-RGD tracers may represent a more easily clinically translatable alternative [50]. Another ⁶⁸Ga-labeled tracer, a ⁶⁸Ga-NOTA-RGD peptidomimetic, was used for angiogenesis imaging in a rat MI model. ⁶⁸Ga-NOTA-RGD uptake was increased in regions of reduced myocardial perfusion and correlated with immunohistochemical staining of CD31 and β₃ integrin (Fig. 2) [51].

Lately, ¹⁸F-Alfatide II (¹⁸F-AlF-NOTA-PRGD2) has been developed as a new promising PET tracer. Taking advantage of the preformation of an aluminum-fluoride complex with consequent attachment of the RGD peptide, time for preparation was significantly reduced and HPLC purification was avoided, while receiving radiochemical purity of over 97 % [80]. The ¹⁸F-Alfatide II tracer was used to characterize angiogenesis in a rat MI model after treatment with vascular endothelial growth factor (VEGF) gene and/or bone marrow mesenchymal stem cells (BMSCs). In this study, ¹⁸F-Alfatide II provided a strong contrast between infarcted and noninfarcted myocardium and uptake was significantly higher in rats treated with VEGF and BMSCs (Fig. 3). Increased uptake of ¹⁸F-Alfatide II correlated with the area of ^99mTc-MIBI uptake defect [20•].

In another study in a rat MI model, the angiogenic potential of 3D HUVEC/cbMSC aggregates was assessed by ⁶⁸Ga-RGD. Injection of 3D HUVEC/cbMSC aggregates resulted in locally increased ⁶⁸Ga-RGD uptake suggesting increased angiogenesis and reduction in defect size [52•]. Using SPECT tracers, an increased uptake of ^99mTc-labeled RGD peptides (^99mTc-RAFT-RGD and 99mTc-NC100692), similar to data of respective ¹⁸F-PET tracers, was found in infarcted myocardium tissue and the border zone of infarction, indicating increased integrin α_vβ₃ expression (Fig. 4) [52•, 81, 82].

Recently, a ⁶⁸Ga-labeled cyclic RGD dimer with a PEG spacer (⁶⁸Ga-PRGD2) was studied for the first time in a small set of patients post-MI. ⁶⁸Ga-PRGD2 uptake was found in 20 of 23 patients around the ischemic regions. Increased uptake was found 1 week after MI and remained high until 2.5 months after MI. ⁶⁸Ga-PRGD2 uptake correlated with size and severity of the infarction (Fig. 5). Three patients who did not show any ⁶⁸Ga-PRGD2 uptake were identified with a very recent MI and events dated back 1–2 years. Nevertheless, ⁶⁸Ga-PRGD2 uptake showed a patchy pattern, which may be attributable to an uptake not only by angiogenic ECs but also interstitial myofibroblasts contributing to myocardial remodeling [55••]. Although the application of integrin α_vβ₃ imaging has been previously translated into clinical trials to assess tumor angiogenesis [83], only a single clinical trial imaging angiogenesis after MI has been conducted so far, with two studies currently recruiting (NCT01813045, NCT01542073).

Even though recent work in integrin α_vβ₃ imaging with PET or SPECT registered substantial improvements, this method is still afflicted with several limitations. Recently, a cyclic RGD moiety conjugated to MPIO (c(RGDyK)-MPIO) for MR angiogenesis visualization in a colorectal carcinoma and melanoma mouse model was studied. c(RGDyK)-MPIO specifically binds to integrin α_vβ₃ expressing vessels, while unbound particles are rapidly cleared from circulation. Specific binding was verified by ex vivo immunolabeling [56•]. Further optimization of MR-based angiogenesis imaging tracers may enable integrated molecular and anatomical imaging.

CEU imaging with targeted microbubbles displays another radiation-free molecular imaging technique. Microbubbles binding to integrin α_vβ₃ and other angiogenesis specific targets have been extensively applied for studying angiogenesis and the response to antiangiogenic therapies in several tumor entities [35, 84‐86]. However, only limited data exist regarding cardiovascular diseases and treatments [87]. Xie et al. investigated the effect of HIF-1α mutant on angiogenesis in a mouse ischemic hind limb model; CEU imaging using α_v-integrin-coated microbubbles has been applied to visualize angiogenesis. Video intensity obtained by α_v imaging positively correlated with ultrasound perfusion imaging data, indicating that CEU imaging may also provide quantitative data on angiogenesis. This suggests that α_v-integrin imaging via ultrasound can be a reliable method to visualize angiogenesis in vivo [34]. Moreover, ultrasound is not only limited to imaging angiogenesis to monitor cardiac regeneration but offers therapeutic options. Microbubbles loaded with therapeutic agents can be dissolved by high acoustic pressures after accumulation at the region of interest, thus enabling targeted drug delivery. Additionally, it is hypothesized that a combination of targeted imaging and drug release via microbubbles is possible [33, 88, 89].

Integrin α₅β₁

Integrin α₅β₁ expression is suggested to be completely restricted to ECs as deletion of the β₁ chain leads to full inhibition of angiogenesis [90]. Analogous to integrin α_vβ₃, expression of integrin α₅β₁ is low in quiescent ECs and upregulated in angiogenic ECs [91, 92]. These results suggest that integrin α₅β₁ could be a more reliable biomarker for angiogenesis compared to α_vβ₃. To assess integrin α₅β₁ imaging in tumor angiogenesis, Notni et al. developed ⁶⁸Ga-aquibeprin (a pseudopeptide targeting integrin α₅β₁) and compared it to ⁶⁸Ga-avebetrin (targeting integrin α_vβ₃). In vitro data showed high affinity for integrin α₅β₁, and no decrease in specificity compared to a previously used ⁶⁸Ga-labeled monomer selectively targeting integrin α₅β₁ was detected. In vivo data showed a higher tumor-to-organ ratio of ⁶⁸Ga-aquibeprin and suggest it to be sufficiently stable. Immunohistochemical stainings further propose integrin α₅β₁ as a more EC specific marker [57••].

Other targets for molecular imaging

CD13

CD13 is a membrane-bound aminopeptidase, which is upregulated on activated ECs [93]. It is considered an important regulator of EC morphogenesis during angiogenesis [94]. The cyclic tripeptide Asn-Gly-Arg (cNGR) binds to CD13 on activated ECs in infarcted myocardium, but not to CD13-positive macrophages in hypoxic myocardium [53, 95]. Comparative studies with RGD and NGR of tumor angiogenesis revealed a threefold higher target homing ratio for NGR [96]. A recent study investigated CD13-targeted angiogenesis imaging in a mouse model of MI with ¹¹¹In-DTPA-cNGR by SPECT. Increased uptake of ¹¹¹In-DTPA-cNGR at day 7 after MI correlated with areas of decreased ^99mTc-sestamibi [53].

CD105

CD105 (endoglin) is a transmembrane protein that is solely expressed on activated ECs [97]. Several PET probes based on TRC105, a monoclonal antibody that binds to CD105 with high avidity, have been tested for tumor angiogenesis imaging [98, 99]. ⁶⁴Cu-NOTA-TRC105 was recently tested to assess angiogenesis in a rat MI model via PET. Tracer uptake was increased in infarcted myocardium. Expression of CD105 was confirmed by immunofluorescence. However, ⁶⁴Cu-NOTA-TRC105 exhibits a long half-life and its intense background signal acted as a confounder [54].

VEGF

VEGF is commonly considered as the most potent mediator of angiogenesis. Consequently, VEGF and its receptors (VEGFRs) are frequently used for angiogenesis imaging. Due to splice variants, several isoforms of VEGF-A exist, of which some are proangiogenic and other antiangiogenic [100]. Monoclonal human anti-VEGF labeled with ¹²³I and ¹²⁴I have been employed for PET/SPECT imaging [101]. In a rat model of myocardial infarction, recombinant radiolabeled VEGF (⁶⁴Cu-DOTA-VEGF₁₂₁) was used for PET imaging of VEGFRs. An increased radiotracer uptake was reported in a period of up to 2 weeks after induction of MI [101].

Several tyrosine kinases are upregulated in heart tissue undergoing angiogenesis and remodeling after MI. Immunohistochemical analyses of MI samples revealed increased levels of VEGFR-2, Tie-2, and PDGFα suggesting its use as an angiogenesis marker in non-invasive molecular imaging. ATV-1 can act as an inhibitor of those kinases. PET imaging with [¹¹C]ATV-1 was assessed in a rat model of MI. Standard uptake values of [¹¹C]ATV-1 correlated with immunohistochemical staining of VEGFR-2, Tie-2, and PDGFα [9].

Conclusions

Even though proangiogenic therapies have so far largely failed as an effective treatment of MI, targeting angiogenesis after MI to mitigate heart failure is still considered a promising strategy. In order to assess the success of such therapeutic interventions in the clinic or in preclinical development, reliable and sensitive noninvasive imaging modalities are needed. Molecular imaging of angiogenesis via PET, SPECT, MRI, and CEU has been investigated intensively within the past decade. A variety of tracers have been translated from tumor angiogenesis models to MI models, and promising results were achieved. These methods offer the unique opportunity to study in vivo molecular mechanisms characterizing myocardial healing after infarction and to evaluate angiogenic effects of regenerative treatments. Combination of high sensitivity PET and SPECT with high-resolution X-ray CT images allows better identification and quantification of tracer uptake within the region of interest. Multimodal imaging with highly specific tracers yields reliable and detailed data of cardiac angiogenesis in small and large animal models and also in humans. Because PET and SPECT imaging use ionizing radiation, these imaging modalities might also expose patients to a risk of growing neoplastic lesions. For clinical applications, further research is warranted to develop radiotracers with a reasonable level of ionizing radiation or even replacing PET and SPECT with MRI or CEU while still featuring high affinity for visualizing growing blood vessels. Continuing development of noninvasive imaging modalities for future clinical applications may enable improved patient risk stratification and pave the way for personalized therapy.

Acknowledgments

Open access funding provided by Medical University of Vienna.

Compliance with Ethics Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

Jetzt testen ³

Cochain C, Channon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal. 2013;18(9):1100–13. doi:10.1089/ars.2012.4849.PubMedPubMedCentralCrossRef

Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378(9792):704–12. doi:10.1016/S0140-6736(11)60894-5.PubMedPubMedCentralCrossRef

Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73(7):333–46.PubMedCrossRef

Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest. 2004;113(12):1684–91. doi:10.1172/JCI20352.PubMedPubMedCentralCrossRef

Uchida Y, Yanagisawa-Miwa A, Nakamura F, Yamada K, Tomaru T, Kimura K, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J. 1995;130(6):1182–8.PubMedCrossRef

Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, et al. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015. doi:10.1161/circresaha.116.304346.PubMedPubMedCentral

Scimia MC, Gumpert AM, Koch WJ. Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther. 2014;14(2):183–95. doi:10.1517/14712598.2014.866085.PubMedCrossRef

Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–87. doi:10.1016/j.cell.2011.08.039.PubMedCrossRef

Dissoki S, Abourbeh G, Salnikov O, Mishani E, Jacobson O. PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. Mol Imaging Biol. 2015;17(2):222–30. doi:10.1007/s11307-014-0790-8.PubMedCrossRef

10.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144.PubMedPubMedCentralCrossRef

11.

Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006;8(11-12):1907–39. doi:10.1089/ars.2006.8.1907.PubMedCrossRef

12.

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569–82.PubMedCrossRef

13.

Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108–18. doi:10.1172/JCI24682.PubMedPubMedCentralCrossRef

14.

Silvestre JS, Smadja DM, Levy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev. 2013;93(4):1743–802. doi:10.1152/physrev.00006.2013.PubMedCrossRef

15.

Jivraj N, Phinikaridou A, Shah AM, Botnar RM. Molecular imaging of myocardial infarction. Basic Res Cardiol. 2014;109(1):397. doi:10.1007/s00395-013-0397-2.PubMedCrossRef

16.

Stacy MR, Sinusas AJ. Emerging imaging modalities in regenerative medicine. Curr Pathobiol Rep. 2015;3(1):27–36. doi:10.1007/s40139-015-0073-3.CrossRef

17.

Ripa RS, Kjaer A. Imaging atherosclerosis with hybrid positron emission tomography/magnetic resonance imaging. Biomed Res Int. 2015;2015:914516. doi:10.1155/2015/914516.PubMedPubMedCentralCrossRef

18.

Stacy MR, Maxfield MW, Sinusas AJ. Targeted molecular imaging of angiogenesis in PET and SPECT: a review. Yale J Biol Med. 2012;85(1):75–86.PubMedPubMedCentral

19.

Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. Nat Biotechnol. 2014;32(8):804–18. doi:10.1038/nbt.2993.PubMedPubMedCentralCrossRef

20.•

Cai M, Ren L, Yin X, Guo Z, Li Y, He T, Tang Y, Long T, Liu Y, Liu G, Zhang X, Hu S. PET monitoring angiogenesis of infarcted myocardium after treatment with vascular endothelial growth factor and bone marrow mesenchymal stem cells. Amino Acids. 2016; 48(3):811-820. doi:10.1007/s00726-015-2129-4. This experimental rat myocardial infarction model introduces a new ¹⁸ F based radiotracer for angiogenesis imaging which offers a variety of advantages over previous radiotracers. Moreover, ¹⁸ F-Alfatide II was used to demonstrate increased myocardial angiogenesis in rats treated with VEGF and/or BMSCs.

21.

Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, et al. Quantitative assessment of atherosclerotic plaques on F-FDG PET/MRI: comparison with a PET/CT hybrid system. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3308-6.

22.

Ratib O, Nkoulou R. Potential applications of PET/MR imaging in cardiology. J Nucl Med. 2014;55(Supplement 2):40S–6. doi:10.2967/jnumed.113.129262.PubMedCrossRef

23.

Stacy MR, Paeng JC, Sinusas AJ. The role of molecular imaging in the evaluation of myocardial and peripheral angiogenesis. Ann Nucl Med. 2015;29(3):217–23. doi:10.1007/s12149-015-0961-y.PubMedPubMedCentralCrossRef

24.

Lee JS, Kim JH. Recent advances in hybrid molecular imaging systems. Semin Musculoskelet Radiol. 2014;18(2):103–22. doi:10.1055/s-0034-1371014.PubMedCrossRef

25.

Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004;363(9427):2162–71. doi:10.1016/S0140-6736(04)16509-4.PubMedCrossRef

26.

Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005;19(14):2008–10. doi:10.1096/fj.05-4145fje.PubMed

27.

Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005;53(3):621–7. doi:10.1002/mrm.20391.PubMedCrossRef

28.

Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4(5):623–6.PubMedCrossRef

29.

Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67(4):1555–62. doi:10.1158/0008-5472.CAN-06-1668.PubMedCrossRef

30.

Leung K. Cyclo(Arg-Gly-Asp-D-Try-Glu) conjugated to ultrasmall superparamagnetic iron oxide nanoparticles. Bethesda (MD): Molecular Imaging and Contrast Agent Database (MICAD); 2004.

31.

Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med. 2010;63(1):33–40. doi:10.1002/mrm.22175.PubMed

32.

Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Reviews. 2010; 1:10.3402/nano.v3401i3400.5358. doi:10.3402/nano.v1i0.5358.

33.

Smith AH, Fujii H, Kuliszewski MA, Leong-Poi H. Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis. J Cardiovasc Transl Res. 2011;4(4):404–15. doi:10.1007/s12265-011-9282-2.PubMedCrossRef

34.

Xie J, Liao Y, Yang L, Wu J, Liu C, Xuan W, et al. Ultrasound molecular imaging of angiogenesis induced by mutant forms of hypoxia-inducible factor-1alpha. Cardiovasc Res. 2011;92(2):256–66. doi:10.1093/cvr/cvr229.PubMedCrossRef

35.

Payen T, Dizeux A, Baldini C, Le Guillou-Buffello D, Lamuraglia M, Comperat E, et al. VEGFR2-targeted contrast-enhanced ultrasound to distinguish between two anti-angiogenic treatments. Ultrasound Med Biol. 2015;41(8):2202–11. doi:10.1016/j.ultrasmedbio.2015.04.010.PubMedCrossRef

36.

Kim JE, Kalimuthu S, Ahn BC. In vivo cell tracking with bioluminescence imaging. Nucl Med Mol Imaging. 2015;49(1):3–10. doi:10.1007/s13139-014-0309-x.PubMedCrossRef

37.

Baker M. Whole-animal imaging: the whole picture. Nature. 2010;463(7283):977–80. doi:10.1038/463977a.PubMedCrossRef

38.

Ahn BC. Applications of molecular imaging in drug discovery and development process. Curr Pharm Biotechnol. 2011;12(4):459–68.PubMedCrossRef

39.

Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: guiding the clinical translation of cardiac stem cell therapy. Circ Res. 2011;109(8):962–79. doi:10.1161/CIRCRESAHA.111.242909.PubMedPubMedCentralCrossRef

40.

Blankstein R, Di Carli MF. Integration of coronary anatomy and myocardial perfusion imaging. Nat Rev Cardiol. 2010;7(4):226–36. doi:10.1038/nrcardio.2010.15.PubMedCrossRef

41.

Gaemperli O, Kaufmann PA, Alkadhi H. Cardiac hybrid imaging. Eur J Nucl Med Mol Imaging. 2014;41 Suppl 1:S91–103. doi:10.1007/s00259-013-2566-9.PubMedCrossRef

42.

Fricke E, Fricke H, Weise R, Kammeier A, Hagedorn R, Lotz N, et al. Attenuation correction of myocardial SPECT perfusion images with low-dose CT: evaluation of the method by comparison with perfusion PET. J Nucl Med. 2005;46(5):736–44.PubMed

43.

Brown ER, Kronmal RA, Bluemke DA, Guerci AD, Carr JJ, Goldin J, et al. Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis. Radiology. 2008;247(3):669–75. doi:10.1148/radiol.2473071469.PubMedCrossRef

44.

Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860–70. doi:10.1016/j.jacc.2006.10.079.PubMedCrossRef

45.

Henzlova MJ, Duvall WL. The future of SPECT MPI: time and dose reduction. J Nucl Cardiol. 2011;18(4):580–7. doi:10.1007/s12350-011-9401-0.PubMedCrossRef

46.

Palyo R, Sinusas A, Liu YH. High-sensitivity and high-resolution SPECT/CT systems provide substantial dose reduction without compromising quantitative precision for assessment of myocardial perfusion or function. J Nucl Med. 2016. doi:10.2967/jnumed.115.164632.PubMed

47.

Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–13. doi:10.1016/S0140-6736(13)61754-7.PubMedCrossRef

48.

Mazurek T, Kobylecka M, Zielenkiewicz M, Kurek A, Kochman J, Filipiak KJ, et al. PET/CT evaluation of F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions’ formation? J Nucl Cardiol. 2016. doi:10.1007/s12350-015-0370-6.PubMed

49.

Iagaru A, Gambhir SS. Imaging tumor angiogenesis: the road to clinical utility. AJR Am J Roentgenol. 2013;201(2):W183–91. doi:10.2214/AJR.12.8568.PubMedCrossRef

50.

Laitinen I, Notni J, Pohle K, Rudelius M, Farrell E, Nekolla SG, et al. Comparison of cyclic RGD peptides for alphavbeta3 integrin detection in a rat model of myocardial infarction. EJNMMI Res. 2013;3(1):38. doi:10.1186/2191-219x-3-38.PubMedPubMedCentralCrossRef

51.

Menichetti L, Kusmic C, Panetta D, Arosio D, Petroni D, Matteucci M, et al. MicroPET/CT imaging of alphavbeta(3) integrin via a novel (6)(8)Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40(8):1265–74. doi:10.1007/s00259-013-2432-9.PubMedCrossRef

52.•

Huang CC, Wei HJ, Lin KJ, Lin WW, Wang CW, Pan WY, Hwang SM, Chang Y, Sung HW. Multimodality noninvasive imaging for assessing therapeutic effects of exogenously transplanted cell aggregates capable of angiogenesis on acute myocardial infarction. Biomaterials. 2015; 73:12-22. doi:10.1016/j.biomaterials.2015.09.009. This is an experimental rat MI study showing that the application of 3D aggregates of HUVECs/cbMSCs improves blood perfusion and global/regional ventricular function. Additionally those aggregates induced increased angiogenesis which was shown in vivo using non-invasive angiogenesis imaging by PET targeting integrin α _v β ₃ and immunohistochemistical stainings.

53.

Hendrikx G, De Saint-Hubert M, Dijkgraaf I, Bauwens M, Douma K, Wierts R, et al. Molecular imaging of angiogenesis after myocardial infarction by (111)In-DTPA-cNGR and (99m)Tc-sestamibi dual-isotope myocardial SPECT. EJNMMI Res. 2015;5:2. doi:10.1186/s13550-015-0081-7.PubMedPubMedCentralCrossRef

54.

Orbay H, Zhang Y, Valdovinos HF, Song G, Hernandez R, Theuer CP, et al. Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging. 2013;4(1):1–9.PubMedPubMedCentral

55.••

Sun Y, Zeng Y, Zhu Y, Feng F, Xu W, Wu C, Xing B, Zhang W, Wu P, Cui L, Wang R, Li F, Chen X, Zhu Z. Application of (68)Ga-PRGD2 PET/CT for alphavbeta3-integrin imaging of myocardial infarction and stroke. Theranostics. 2014; 4(8):778-786. doi:10.7150/thno.8809. This trial is the first larger trial in humans on angiogenesis after myocardial infarction. It offers an insight into the role of angiogenesis throught myocardial healing after infarction and provides evidence that PET imaging of integrin α _v β ₃ is feasable.

56.•

Melemenidis S, Jefferson A, Ruparelia N, Akhtar AM, Xie J, Allen D, et al. Molecular magnetic resonance imaging of angiogenesis in vivo using polyvalent cyclic RGD-iron oxide microparticle conjugates. Theranostics. 2015;5(5):515–29. doi:10.7150/thno.10319. This study on tumour angiogenesis in mice shows for the first time representative in vivo angiogenesis imaging using RGD-targeted MPIOs in MRI.PubMedPubMedCentralCrossRef

57.••

Notni J, Steiger K, Hoffmann F, Reich D, Kapp TG, Rechenmacher F, Neubauer S, Kessler H, Wester HJ. Complementary, selective PET imaging of integrin subtypes alpha5beta1 and alphavbeta3 using 68Ga-aquibeprin and 68Ga-avebetrin. J Nucl Med. 2016; 57(3):460-466. doi:10.2967/jnumed.115.165720. This trial compares for the first time molecular imaging of myocardial angiogenesis in rat with MI two integrin subtypes. The so far rather neglected integrin α ₅ β ₁ was demonstrated to be more specific for activated endothelial cells with however no decline in affinity.

58.

Dobrucki LW, de Muinck ED, Lindner JR, Sinusas AJ. Approaches to multimodality imaging of angiogenesis. J Nucl Med. 2010. doi:10.2967/jnumed.110.074963.PubMedCentral

59.

Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol. 2006;18(5):579–86. doi:10.1016/j.ceb.2006.08.005.PubMedPubMedCentralCrossRef

60.

Humphries MJ. Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol Sci. 2000;21(1):29–32.PubMedCrossRef

61.

Horton MA. The alpha v beta 3 integrin “vitronectin receptor”. Int J Biochem Cell Biol. 1997;29(5):721–5.PubMedCrossRef

62.

Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78(2):395–403. doi:10.1093/cvr/cvn033.PubMedCrossRef

63.

Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 1998;95(4):507–19.PubMedCrossRef

64.

Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8(1):27–34. doi:10.1038/nm0102-27.PubMedCrossRef

65.

Reynolds AR, Reynolds LE, Nagel TE, Lively JC, Robinson SD, Hicklin DJ, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 2004;64(23):8643–50. doi:10.1158/0008-5472.CAN-04-2760.PubMedCrossRef

66.

Atkinson SJ, Ellison TS, Steri V, Gould E, Robinson SD. Redefining the role(s) of endothelial alphavbeta3-integrin in angiogenesis. Biochem Soc Trans. 2014;42(6):1590–5. doi:10.1042/BST20140206.PubMedCrossRef

67.

Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging alpha(v)beta(3) integrin levels. Radiology. 2011;260(1):182–91. doi:10.1148/radiol.11101139.PubMedPubMedCentralCrossRef

68.

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49(1):22–9. doi:10.2967/jnumed.107.045864.PubMedCrossRef

69.

Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22(12):2415–22. doi:10.1021/bc200197h.PubMedPubMedCentralCrossRef

70.

Zhu Z, Yin Y, Zheng K, Li F, Chen X, Zhang F, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using (6)(8)Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis. 2014;73(6):1269–72. doi:10.1136/annrheumdis-2013-204820.PubMedPubMedCentralCrossRef

71.

Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6(5):350–9. doi:10.1016/j.mibio.2004.06.004.PubMedCrossRef

72.

Lang L, Li W, Jia HM, Fang DC, Zhang S, Sun X, et al. New methods for labeling RGD peptides with bromine-76. Theranostics. 2011;1:341–53.PubMedPubMedCentralCrossRef

73.

Jacobson O, Zhu L, Niu G, Weiss ID, Szajek LP, Ma Y, et al. MicroPET imaging of integrin alphavbeta3 expressing tumors using 89Zr-RGD peptides. Mol Imaging Biol. 2011;13(6):1224–33. doi:10.1007/s11307-010-0458-y.PubMedPubMedCentralCrossRef

74.

Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study G. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51(1):40–6. doi:10.3109/02841850903273974.PubMedCrossRef

75.

Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin alphavbeta3-selective radiotracer 99mTc-3PRGD 2 in non-human primates. Mol Imaging Biol. 2011;13(4):730–6. doi:10.1007/s11307-010-0385-y.PubMedCrossRef

76.

Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, et al. Imaging integrin alphavbeta3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. J Nucl Med. 2014;55(2):281–6. doi:10.2967/jnumed.113.129668.PubMedCrossRef

77.

Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, et al. Molecular imaging of early alphavbeta3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med. 2012;53(2):318–23. doi:10.2967/jnumed.111.091652.PubMedCrossRef

78.

Notni J, Pohle K, Wester HJ. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of (6)(8)Ga-TRAP(RGD)(3). Nucl Med Biol. 2013;40(1):33–41. doi:10.1016/j.nucmedbio.2012.08.006.PubMedCrossRef

79.

Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39(6):777–84. doi:10.1016/j.nucmedbio.2012.02.006.PubMedCrossRef

80.

Gao H, Lang L, Guo N, Cao F, Quan Q, Hu S, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin targeted tracer (18)F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012;39(4):683–92. doi:10.1007/s00259-011-2052-1.PubMedPubMedCentralCrossRef

81.

Dimastromatteo J, Riou LM, Ahmadi M, Pons G, Pellegrini E, Broisat A, et al. In vivo molecular imaging of myocardial angiogenesis using the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol. 2010;17(3):435–43. doi:10.1007/s12350-010-9191-9.PubMedCrossRef

82.

Paeng JC, Bregasi A, Sahul Z, Kalinowski L, Dobrucki LW, Brennan M, et al. Serial reference tissue-based quantitative and volumetric analysis of integrin-targeted angiogenesis imaging: chronic canine model of myocardial infarction. J Nucl Med. 2014;2014(55):1710.

83.

Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S126–38. doi:10.1007/s00259-011-2028-1.PubMedCrossRef

84.

Hu Q, Wang XY, Kang LK, Wei HM, Xu CM, Wang T, et al. RGD-targeted ultrasound contrast agent for longitudinal assessment of Hep-2 tumor angiogenesis in vivo. PLoS One. 2016;11(2):e0149075. doi:10.1371/journal.pone.0149075.PubMedPubMedCentralCrossRef

85.

Shelton SE, Lindsey BD, Tsuruta JK, Foster FS, Dayton PA. Molecular acoustic angiography: a new technique for high-resolution superharmonic ultrasound molecular imaging. Ultrasound Med Biol. 2016;42(3):769–81. doi:10.1016/j.ultrasmedbio.2015.10.015.PubMedCrossRef

86.

Yan F, Xu X, Chen Y, Deng Z, Liu H, Xu J, et al. A lipopeptide-based alphavbeta(3) integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis. Ultrasound Med Biol. 2015;41(10):2765–73. doi:10.1016/j.ultrasmedbio.2015.05.023.PubMedCrossRef

87.

Leong-Poi H. Molecular imaging using contrast-enhanced ultrasound: evaluation of angiogenesis and cell therapy. Cardiovasc Res. 2009;84(2):190–200. doi:10.1093/cvr/cvp248.PubMedCrossRef

88.

Deng Q, Hu B, Cao S, Song HN, Chen JL, Zhou Q. Improving the efficacy of therapeutic angiogenesis by UTMD-mediated Ang-1 gene delivery to the infarcted myocardium. Int J Mol Med. 2015;36(2):335–44. doi:10.3892/ijmm.2015.2226.PubMedPubMedCentral

89.

Nguyen AT, Wrenn SP. Acoustically active liposome-nanobubble complexes for enhanced ultrasonic imaging and ultrasound-triggered drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(3):316–25. doi:10.1002/wnan.1255.PubMedCrossRef

90.

Fassler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995;9(15):1896–908.PubMedCrossRef

91.

Tanjore H, Zeisberg EM, Gerami-Naini B, Kalluri R. Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn. 2008;237(1):75–82. doi:10.1002/dvdy.21385.PubMedCrossRef

92.

Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156(4):1345–62.PubMedPubMedCentralCrossRef

93.

Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112(7):2628–35. doi:10.1182/blood-2008-04-150862.PubMedPubMedCentralCrossRef

94.

Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652–9.PubMedPubMedCentralCrossRef

95.

Buehler A, van Zandvoort MA, Stelt BJ, Hackeng TM, Schrans-Stassen BH, Bennaghmouch A, et al. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol. 2006;26(12):2681–7. doi:10.1161/01.ATV.0000245807.65714.0b.PubMedCrossRef

96.

Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377–80.PubMedCrossRef

97.

Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets. 2003;3(6):427–32.PubMedCrossRef

98.

Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, et al. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab’)(2) antibody fragment. Mol Pharm. 2013;10(2):709–16. doi:10.1021/mp300507r.PubMedPubMedCentralCrossRef

99.

Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S, et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res. 2012;4(3):333–46.PubMedPubMedCentral

100.

Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121(20):3487–95. doi:10.1242/jcs.016410.PubMedPubMedCentralCrossRef

101.

Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, et al. Characterization of 123I-vascular endothelial growth factor–binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. Int J Cancer. 2001;91(6):789–96. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.0.CO;2-K.PubMedCrossRef

Titel: Molecular Imaging of Angiogenesis in Cardiac Regeneration
verfasst von: Ljubica Mandic
Denise Traxler
Alfred Gugerell
Katrin Zlabinger
Dominika Lukovic
Noemi Pavo
Georg Goliasch
Andreas Spannbauer
Johannes Winkler
Mariann Gyöngyösi
Publikationsdatum: 01.10.2016
Verlag: Springer US
Erschienen in: Current Cardiovascular Imaging Reports / Ausgabe 10/2016
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-016-9389-6

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molecular Imaging of Angiogenesis in Cardiac Regeneration

Abstract

Purpose of Review

Recent Findings

Summary

Introduction

Angiogenesis

Molecular Imaging Tools

Nuclear Imaging

MRI

Ultrasound Molecular Imaging

Bioluminescence Imaging

Multimodal Imaging

Molecular Imaging of Myocardial Angiogenesis

Integrins

Integrin α_vβ₃

Integrin α₅β₁

Other targets for molecular imaging

CD13

CD105

VEGF

Conclusions

Acknowledgments

Compliance with Ethics Standards

Conflict of Interest

Human and Animal Rights and Informed Consent

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

e.Med Radiologie

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Introduction

Angiogenesis

Molecular Imaging Tools

Nuclear Imaging

MRI

Ultrasound Molecular Imaging

Bioluminescence Imaging

Multimodal Imaging

Molecular Imaging of Myocardial Angiogenesis

Integrins

Integrin αvβ3

Integrin α5β1

Other targets for molecular imaging

CD13

CD105

VEGF

Conclusions

Acknowledgments

Compliance with Ethics Standards

Conflict of Interest

Human and Animal Rights and Informed Consent

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

e.Med Radiologie

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Integrin α_vβ₃

Integrin α₅β₁